<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background ME-143, a second-generation <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific <z:chebi fb="0" ids="16908">NADH</z:chebi> oxidase inhibitor, is broadly active against human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> in vitro and in vivo </plain></SENT>
<SENT sid="1" pm="."><plain>This first-in-human dose-escalation study evaluated the dose-limiting toxicities (DLTs), pharmacokinetics, safety, tolerability, and preliminary anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity of ME-143 in patients with advanced <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Methods Patients with advanced <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> were treated in a 3 + 3 escalation design </plain></SENT>
<SENT sid="3" pm="."><plain>ME-143 was administered via intravenous infusion on days 1, 8, and 15 of the first 28-day cycle, and weekly thereafter; the final cohort received twice-weekly treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Samples for pharmacokinetic analysis were collected during cycle 1 </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment continued until disease progression or unacceptable toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>Results Eighteen patients were treated: 2.5 mg/kg (n = 3); 5 mg/kg (n = 3); 10 mg/kg (n = 3); 20 mg/kg (n = 6); 20 mg/kg twice-weekly (n = 3) </plain></SENT>
<SENT sid="7" pm="."><plain>There were no DLTs observed </plain></SENT>
<SENT sid="8" pm="."><plain>Nearly <z:hpo ids='HP_0000001'>all</z:hpo> treatment-related toxicities were grade 1/2, specifically (<z:hpo ids='HP_0000001'>all</z:hpo> grades) <z:hpo ids='HP_0002018'>nausea</z:hpo> (22 %) and <z:mp ids='MP_0002899'>fatigue</z:mp> (17 %) </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients experienced infusion reactions at the 20 mg/kg dose level, one of which was grade 4 </plain></SENT>
<SENT sid="10" pm="."><plain>Stable disease was documented in three patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:mpath ids='MPATH_354'>cholangiocarcinoma</z:mpath>, and <z:e sem="disease" ids="C0153446" disease_type="Neoplastic Process" abbrv="">anal cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Pharmacokinetic exposures were linear and dose-dependent, with a half-life of approximately 5 h </plain></SENT>
<SENT sid="12" pm="."><plain>Conclusions ME-143 was well-tolerated when administered intravenously at the maximally administered/recommended phase 2 dose of 20 mg/kg once weekly to patients with advanced <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>Though limited clinical activity was observed with monotherapy, inhibitors of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific <z:chebi fb="0" ids="16908">NADH</z:chebi> oxidase such as ME-143 may derive their greatest benefit in combination with cytotoxic chemotherapy </plain></SENT>
</text></document>